Viktor Aleksandrovich Balayants
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Viktor Aleksandrovich Balayants has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Alla Mikhailovna Kovrigina
National Medical Research Center for Hematology
2 shared publications - Anastasia Yurievna Efimenko
Lomonosov Moscow State University
1 shared publication - Daria Aleksandrovna Koroleva
National Medical Research Center for Hematology
1 shared publication - Dmitry Stambolsky
Lomonosov Moscow State University
1 shared publication - E. E. Tsukanov
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
1 shared publication - E. O. Kiselev
Moscow Botkin Multidisciplinary Scientific-Clinical Center, Department of Health of the City of Moscow
1 shared publication
Latest Publications
- Open Access
- 21 December 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (4) , 530-541
Primary central nervous system Burkitt lymphoma: Case report and literature review
Introduction. Burkitt lymphoma is an aggressive B-cell lymphoma characterized by pathomorphological, immunophenotypic, and cytogenetic features that are the main criteria for its diagnosis. Burkitt lymphoma with isolated involvement of the central nervous system (CNS) is an extremely rare nosological form of primary lymphoma of the central nervous system. The small number of observations in the literature does not allow us to fully determine the main clinical, radiological and age-related features of this lymphoma, as well as standardize the treatment tactics for patients with primary Burkitt lymphoma of the central nervous system. Aim: to present a clinical case of a patient with primary Burkitt lymphoma of the CNS with damage to the right hemisphere of the cerebellum and brainstem with compression of the cavity of the fourth ventricle. Main findings . The diagnosis was established based on the basis of pathomorphological and immunohistochemical examination of the removed neoplasm of the fourth ventricle and was confirmed by in situ fluorescence hybridization using the DNA probe MYC gene break apart detection dual-color probe, which revealed a classical translocation involving the MYC/8q24 gene. The patient underwent 4 courses of chemotherapy under the LB-M-04 program, at the end of which a regression of the neoplasm was achieved.
- 21 December 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (4) , 530-541
Open AccessPrimary central nervous system Burkitt lymphoma: Case report and literature review
Introduction. Burkitt lymphoma is an aggressive B-cell lymphoma characterized by pathomorphological, immunophenotypic, and cytogenetic features that are the main criteria for its diagnosis. Burkitt lymphoma with isolated involvement of the central nervous system (CNS) is an extremely rare nosological form of primary lymphoma of the central nervous system. The small number of observations in the literature does not allow us to fully determine the main clinical, radiological and age-related features of this lymphoma, as well as standardize the treatment tactics for patients with primary Burkitt lymphoma of the central nervous system. Aim: to present a clinical case of a patient with primary Burkitt lymphoma of the CNS with damage to the right hemisphere of the cerebellum and brainstem with compression of the cavity of the fourth ventricle. Main findings . The diagnosis was established based on the basis of pathomorphological and immunohistochemical examination of the removed neoplasm of the fourth ventricle and was confirmed by in situ fluorescence hybridization using the DNA probe MYC gene break apart detection dual-color probe, which revealed a classical translocation involving the MYC/8q24 gene. The patient underwent 4 courses of chemotherapy under the LB-M-04 program, at the end of which a regression of the neoplasm was achieved.
- Open Access
- 1 October 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (4) , 293-304
The 5-Year Experience of the Reference Center for Differential Diagnosis of Hematolymphoid Tumors Based at the National Research Center for Hematology
In the framework of the federal project “Cancer Management” in accordance with the Decree of the Ministry of Health of the Russian Federation in 2020, at the pathology department of the National Research Center for Hematology, a reference center was established for immunohistochemical (IHC) and pathomorphological studies in adult patients with hematopathology. The present paper analyzes the activities of this reference center in the period from 2020 to 2024. Within that time, it conducted 24,101 studies using histological, histochemical, and IHC methods of analyzing biopsy/surgical specimens with antemortem pathology protocols and pathomorphological reports. The next step was to provide an expert comparison between the referral pathomorphological diagnosis received from different healthcare institutions and the pathomorphological diagnosis determined at the reference center. In addition to that, the analysis was focused on 825 histoscans received by the National Research Center for Hematology upon requests from the Federal Telemedicine Service (TMS). In the period of 2020–2024, there appeared to be a considerable increase in the number of senders of biopsy/surgical specimens (from 51 to 80) in the Russian Federation and in-life protocols (from 1939 to 3877, the maximum of 9413 was in 2021). The comparison of the referral diagnosis with the diagnosis based on the studies at the reference center yielded an average difference of 30 %. A total of 14,434 lymphoid tumors were diagnosed including 63 % of B-cell, 12 % of T-cell, and 19 % of Hodgkin lymphomas, among which the nodular variant accounted for 10 %. In 6 % of cases, for this or that reason,the nosology verification did not seem possible. In 75 % of primary skin lymphomas, mycosis fungoides was identified with half of cases (48–52 %) diagnosed as non-neoplastic dermatosis/dermatitis on the basis of skin biopsy analysis with lymphoma suspicion. The comparison of the referral diagnosis based on histoscans by TMS request with the diagnosis of the reference center revealed only modest similarity of 27–45 %. Therefore, the reference center model of the Ministry of Health of the Russian Federation specializing in different fields of oncopathology, and hematopathology in particular, proved its effectiveness and urgency throughout 2020–2024. Accordingly, there is a crucial need for support and development of reference centers for pathomorphological and IHC methods of studies, while legal and finance issues accumulated over 5 years still remain to be resolved.
- 1 October 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (4) , 293-304
Open AccessThe 5-Year Experience of the Reference Center for Differential Diagnosis of Hematolymphoid Tumors Based at the National Research Center for Hematology
In the framework of the federal project “Cancer Management” in accordance with the Decree of the Ministry of Health of the Russian Federation in 2020, at the pathology department of the National Research Center for Hematology, a reference center was established for immunohistochemical (IHC) and pathomorphological studies in adult patients with hematopathology. The present paper analyzes the activities of this reference center in the period from 2020 to 2024. Within that time, it conducted 24,101 studies using histological, histochemical, and IHC methods of analyzing biopsy/surgical specimens with antemortem pathology protocols and pathomorphological reports. The next step was to provide an expert comparison between the referral pathomorphological diagnosis received from different healthcare institutions and the pathomorphological diagnosis determined at the reference center. In addition to that, the analysis was focused on 825 histoscans received by the National Research Center for Hematology upon requests from the Federal Telemedicine Service (TMS). In the period of 2020–2024, there appeared to be a considerable increase in the number of senders of biopsy/surgical specimens (from 51 to 80) in the Russian Federation and in-life protocols (from 1939 to 3877, the maximum of 9413 was in 2021). The comparison of the referral diagnosis with the diagnosis based on the studies at the reference center yielded an average difference of 30 %. A total of 14,434 lymphoid tumors were diagnosed including 63 % of B-cell, 12 % of T-cell, and 19 % of Hodgkin lymphomas, among which the nodular variant accounted for 10 %. In 6 % of cases, for this or that reason,the nosology verification did not seem possible. In 75 % of primary skin lymphomas, mycosis fungoides was identified with half of cases (48–52 %) diagnosed as non-neoplastic dermatosis/dermatitis on the basis of skin biopsy analysis with lymphoma suspicion. The comparison of the referral diagnosis based on histoscans by TMS request with the diagnosis of the reference center revealed only modest similarity of 27–45 %. Therefore, the reference center model of the Ministry of Health of the Russian Federation specializing in different fields of oncopathology, and hematopathology in particular, proved its effectiveness and urgency throughout 2020–2024. Accordingly, there is a crucial need for support and development of reference centers for pathomorphological and IHC methods of studies, while legal and finance issues accumulated over 5 years still remain to be resolved.
- Open Access
- 8 June 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (6) , 1346
Urokinase-Type Plasminogen Activator Enhances the Neuroprotective Activity of Brain-Derived Neurotrophic Factor in a Model of Intracerebral Hemorrhage
Brain-derived neurotrophic factor (BDNF) is a classic neuroprotective and pro-regenerative factor in peripheral and central nervous tissue. Its ability to stimulate the restoration of damaged nerve and brain tissue after ischemic stroke and intraventricular hemorrhage has been demonstrated. However, the current concept of regeneration allows us to assert that one factor, even if essential, cannot be the sole contributor to this complex biological process. We have previously shown that urokinase-type plasminogen activator (uPA) complements BDNF activity and stimulates restoration of nervous tissue. Using a model of intracerebral hemorrhage in rats, we investigated the neurotrophic and neuroprotective effect of BDNF combined with uPA. The local simultaneous administration of BDNF and uPA provided effective neuroprotection of brain tissue after intracerebral hemorrhage, promoted survival of experimental animals and their neurological recovery, and decreased lesion volume. The study of cellular mechanisms of the observed neurotrophic effect of BDNF and uPA combination revealed both known mechanisms (neuronal survival and neurite growth) and new ones (microglial activation) that had not been shown for BDNF and uPA. Our findings support the concept of using combinations of biological factors with diverse but complementary mechanisms of action as a promising regenerative approach.
- 8 June 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (6) , 1346
Open AccessUrokinase-Type Plasminogen Activator Enhances the Neuroprotective Activity of Brain-Derived Neurotrophic Factor in a Model of Intracerebral Hemorrhage
Brain-derived neurotrophic factor (BDNF) is a classic neuroprotective and pro-regenerative factor in peripheral and central nervous tissue. Its ability to stimulate the restoration of damaged nerve and brain tissue after ischemic stroke and intraventricular hemorrhage has been demonstrated. However, the current concept of regeneration allows us to assert that one factor, even if essential, cannot be the sole contributor to this complex biological process. We have previously shown that urokinase-type plasminogen activator (uPA) complements BDNF activity and stimulates restoration of nervous tissue. Using a model of intracerebral hemorrhage in rats, we investigated the neurotrophic and neuroprotective effect of BDNF combined with uPA. The local simultaneous administration of BDNF and uPA provided effective neuroprotection of brain tissue after intracerebral hemorrhage, promoted survival of experimental animals and their neurological recovery, and decreased lesion volume. The study of cellular mechanisms of the observed neurotrophic effect of BDNF and uPA combination revealed both known mechanisms (neuronal survival and neurite growth) and new ones (microglial activation) that had not been shown for BDNF and uPA. Our findings support the concept of using combinations of biological factors with diverse but complementary mechanisms of action as a promising regenerative approach.